{"id":24243,"date":"2019-02-21T07:30:22","date_gmt":"2019-02-21T06:30:22","guid":{"rendered":"https:\/\/wordpress-783423-2671269.cloudwaysapps.com\/?p=24243"},"modified":"2025-01-29T13:43:38","modified_gmt":"2025-01-29T12:43:38","slug":"21-february-2019-dermapharm-continues-to-drive-development-of-new-products","status":"publish","type":"post","link":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/","title":{"rendered":"<span id=\"2019\" class=\"Postdate\">February 21, 2019<\/span> | Dermapharm continues to drive development of new products"},"content":{"rendered":"<style> .zur\u00fcckbutton:before {display: inline-block; font-family: \"ETmodules\"; content: \"4a\"; color: #00225f; margin-right: 7px;} .zur\u00fcckbutton:hover:before {display: inline-block; font-family: \"ETmodules\"; content: \"4a\"; color: #d85710; margin-right: 7px;}<\/style>\n<h1>Corporate news<\/h1>\n<p><a class=\"zur\u00fcckbutton\" href=\"https:\/\/cometis.de\/en\/publication-archive-dermapharm\">to the archive<\/a><\/p>\n<h1>Dermapharm continues to drive development of new products<\/h1>\n<ul>\n<li><strong>New products for the treatment of acute hay fever symptoms open up significant market potential<\/strong><\/li>\n<li><strong>bite away<sup>\u00ae<\/sup> successful in all distribution channels and receives award as one of the OTC growth champions<\/strong><\/li>\n<\/ul>\n<p><strong>Gr\u00fcnwald, February 21, 2019 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil\u00ae and Momekort\u00ae in Germany just in time for the hay fever season. In addition, the patented medical product bite away\u00ae from the 2018 Hyperthermia range has performed well in all sales channels.<\/strong><\/p>\n<p>Since January 2019, Dermapharm has been offering the self-developed product Azedil\u00ae in Germany for treatment of acute hay fever problems in the eyes and nose. Azedil\u00ae is an antihistamine that is available individually as both a nasal spray and eye drops or in a combination pack. Dermapharm has also been offering Momekort\u00ae, a prescription-free nasal spray for adults that contains cortisone, for more severe symptoms caused by allergic symptoms of the nose since February 2019. The nasal spray has a local anti-allergic, anti-inflammatory and decongestant effect against hay fever symptoms. Momekort\u00ae has no sedative or habituation effect and can therefore be used throughout the entire hay fever season.<\/p>\n<p>Due to the strong increase in allergies in the population, the demand for anti-allergic preparations is constantly growing(1). Just in time for the start of the main season for hay fever, which is usually from February to the end of July, Dermapharm has already stocked many pharmacies in Germany with the products Azedil\u00ae and Momekort\u00ae.<\/p>\n<p>Dermapharm had already strengthened its OTC portfolio with the hyperthermal medical product bite away\u00ae at the end of 2017. The patented product is used for the symptomatic treatment of itching, pain and swelling caused by insect bites and stings. Since the acquisition of the technology, Dermapharm has been able to market bite away\u00ae very successfully in Germany and many other countries.<\/p>\n<p>In 2018, the specialist magazine \u201cHEALTHCARE MARKETING,\u201d in cooperation with the market research institute \u201cInsight Health,\u201d has identified bite away\u00ae to be one of the fastest growing OTC products in pharmacies \u2013 offline and online. bite away has also developed very positively in other channels such as drugstores and e-commerce, occupying the top positions in the respective segments.<\/p>\n<p>(1) European Centre for Allergy Research Foundation, Allergies \u2013 Facts and Figures, 2018.<\/p>\n<div class=\"leseprobe-archiv\"><a title=\"Post as PDF\" href=\"https:\/\/cometis.de\/wp-content\/uploads\/2019\/02\/20190221_CN_Dermapharm_Business_Update_EN.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Post as PDF<\/a><\/div>\n<style> .leseprobe-archiv {color: #00225f !important; border-color: #00225f; position: relative; padding: 0.3em 1em; border: 1px solid; -webkit-border-radius: 3px; -moz-border-radius: 3px; border-radius: 3px; -webkit-transition: all 0.2s; -moz-transition: all 0.2s; transition: all 0.2s; padding:10px; width: 19%; text-align: center; margin-right: 10px; float:left;} .leseprobe-archiv:hover {background-color: #eee; border-color: #ffffff; cursor: pointer;}<\/style>\n","protected":false},"excerpt":{"rendered":"<p>Gr\u00fcnwald, February 21, 2019 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil\u00ae and Momekort\u00ae in Germany just in time for the hay fever season. In addition, the patented medical product bite away\u00ae from the 2018 Hyperthermia range has performed well in all sales channels.<\/p>\n","protected":false},"author":2,"featured_media":98872,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[215,90],"tags":[260],"class_list":["post-24243","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dermapharm-corporate-news-en","category-news-en","tag-2019-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.2 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>February 21, 2019 | Dermapharm continues to drive development of new products - cometis AG<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"February 21, 2019 | Dermapharm continues to drive development of new products\" \/>\n<meta property=\"og:description\" content=\"Gr\u00fcnwald, February 21, 2019 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil\u00ae and Momekort\u00ae in Germany just in time for the hay fever season. In addition, the patented medical product bite away\u00ae from the 2018 Hyperthermia range has performed well in all sales channels.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/\" \/>\n<meta property=\"og:site_name\" content=\"cometis AG\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-21T06:30:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T12:43:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"171\" \/>\n\t<meta property=\"og:image:height\" content=\"31\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Assistenz cometis AG\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Assistenz cometis AG\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/\"},\"author\":{\"name\":\"Assistenz cometis AG\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\"},\"headline\":\"February 21, 2019 | Dermapharm continues to drive development of new products\",\"datePublished\":\"2019-02-21T06:30:22+00:00\",\"dateModified\":\"2025-01-29T12:43:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/\"},\"wordCount\":400,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"keywords\":[\"2019\"],\"articleSection\":[\"Dermapharm Corporate News\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/\",\"name\":\"February 21, 2019 | Dermapharm continues to drive development of new products - cometis AG\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"datePublished\":\"2019-02-21T06:30:22+00:00\",\"dateModified\":\"2025-01-29T12:43:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/icon_newsroom.svg\",\"width\":172,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"February 21, 2019 | Dermapharm continues to drive development of new products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"name\":\"cometis AG\",\"description\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#organization\",\"name\":\"cometis AG\",\"alternateName\":\"Deutschlands f\u00fchrende Investor Relations Agentur\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"contentUrl\":\"https:\\\/\\\/www.cometis.de\\\/wp-content\\\/uploads\\\/2024\\\/12-old\\\/Cometis-Mobile-Logo-1.png\",\"width\":171,\"height\":31,\"caption\":\"cometis AG\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cometis-ag\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/cometisAG\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/#\\\/schema\\\/person\\\/5359bae3178840cd846706150aa69cd1\",\"name\":\"Assistenz cometis AG\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g\",\"caption\":\"Assistenz cometis AG\"},\"url\":\"https:\\\/\\\/www.cometis.de\\\/en\\\/author\\\/assistenz-cometis-ag\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"February 21, 2019 | Dermapharm continues to drive development of new products - cometis AG","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/","og_locale":"en_US","og_type":"article","og_title":"February 21, 2019 | Dermapharm continues to drive development of new products","og_description":"Gr\u00fcnwald, February 21, 2019 \u2013 Dermapharm Holding SE (\u201cDermapharm\u201d), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil\u00ae and Momekort\u00ae in Germany just in time for the hay fever season. In addition, the patented medical product bite away\u00ae from the 2018 Hyperthermia range has performed well in all sales channels.","og_url":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/","og_site_name":"cometis AG","article_published_time":"2019-02-21T06:30:22+00:00","article_modified_time":"2025-01-29T12:43:38+00:00","og_image":[{"width":171,"height":31,"url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","type":"image\/png"}],"author":"Assistenz cometis AG","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Assistenz cometis AG","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#article","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/"},"author":{"name":"Assistenz cometis AG","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1"},"headline":"February 21, 2019 | Dermapharm continues to drive development of new products","datePublished":"2019-02-21T06:30:22+00:00","dateModified":"2025-01-29T12:43:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/"},"wordCount":400,"publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"image":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","keywords":["2019"],"articleSection":["Dermapharm Corporate News","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/","url":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/","name":"February 21, 2019 | Dermapharm continues to drive development of new products - cometis AG","isPartOf":{"@id":"https:\/\/www.cometis.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#primaryimage"},"image":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","datePublished":"2019-02-21T06:30:22+00:00","dateModified":"2025-01-29T12:43:38+00:00","breadcrumb":{"@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#primaryimage","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2022\/06\/icon_newsroom.svg","width":172,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/www.cometis.de\/en\/21-february-2019-dermapharm-continues-to-drive-development-of-new-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cometis.de\/en\/"},{"@type":"ListItem","position":2,"name":"February 21, 2019 | Dermapharm continues to drive development of new products"}]},{"@type":"WebSite","@id":"https:\/\/www.cometis.de\/en\/#website","url":"https:\/\/www.cometis.de\/en\/","name":"cometis AG","description":"Deutschlands f\u00fchrende Investor Relations Agentur","publisher":{"@id":"https:\/\/www.cometis.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cometis.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cometis.de\/en\/#organization","name":"cometis AG","alternateName":"Deutschlands f\u00fchrende Investor Relations Agentur","url":"https:\/\/www.cometis.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","contentUrl":"https:\/\/www.cometis.de\/wp-content\/uploads\/2024\/12-old\/Cometis-Mobile-Logo-1.png","width":171,"height":31,"caption":"cometis AG"},"image":{"@id":"https:\/\/www.cometis.de\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cometis-ag\/","https:\/\/www.youtube.com\/user\/cometisAG"]},{"@type":"Person","@id":"https:\/\/www.cometis.de\/en\/#\/schema\/person\/5359bae3178840cd846706150aa69cd1","name":"Assistenz cometis AG","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/43da04bfaca4f56c43243bf29c1e464e0dbbc04dfd398bead7b5594ba02bcec9?s=96&d=mm&r=g","caption":"Assistenz cometis AG"},"url":"https:\/\/www.cometis.de\/en\/author\/assistenz-cometis-ag\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/24243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/comments?post=24243"}],"version-history":[{"count":0,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/posts\/24243\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media\/98872"}],"wp:attachment":[{"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/media?parent=24243"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/categories?post=24243"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cometis.de\/en\/wp-json\/wp\/v2\/tags?post=24243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}